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Abstract 
Chromosome 17q21.31 microdeletion was one of the first genomic disorders identified by 
chromosome microarrays. We report here the clinical and molecular characterization of a new 
series of 14 French patients with this microdeletion syndrome. The most frequent clinical 
features were hypotonia, developmental delay and facial dysmorphism, but scaphocephaly, 
prenatal ischemic infarction and perception deafness were also described. Genotyping of the 
parents showed that the parent from which the abnormality was inherited carried the H2 
inversion polymorphism, confirming that the H2 allele is necessary, but not sufficient to 
generate the 17q21.31 microdeletion. Previously reported molecular analyses of patients with 
17q21.31 microdeletion syndrome defined a 493 kb genomic fragment that was deleted in 
most patients after taking into account frequent copy number variations in normal controls, 
but the deleted interval was significantly smaller (205 kb) in one of our patients, 
encompassing only the MAPT, STH and KIAA1267 genes. As this patient presents the 
classical phenotype of 17q21.31 syndrome, these data make it possible to define a new 
minimal critical region of 160.8 kb, strengthening the evidence for involvement of the MAPT 
gene in this syndrome. 
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Introduction 
Array comparative genomic hybridization (aCGH) has revolutionized the diagnosis of mental 
retardation through the use of a “reverse phenotyping” approach making it possible to identify 
recurrent genomic rearrangements before their clinical description [1]. Such techniques led to 
the recent characterization of novel microdeletion and microduplication syndromes [2,3,4]. A 
recurrent 17q21.31 microdeletion [Mendelian Inheritance in Man (MIM) #610443], resulting 
in the loss of a 500 to 650 kb region between low-copy repeat (LCR) regions, was first 
described in 2006 in mentally retarded individuals with a clearly recognizable clinical 
phenotype of mental retardation, hypotonia and characteristic facial features [5,6,7]. The 
complex genomic architecture of this microdeletion, with large clusters of LCRs at the 
breakpoints, suggested an underlying mechanism of non allelic homologous recombination 
(NAHR) [8]. A common 900 kb inversion polymorphism occurs in this region, and 
chromosomes with the inverted fragment in different orientations correspond to two different 
haplotypes, H1 and H2 [9]. The direct orientation of LCRs flanking the deleted fragment in 
the H2 haplotype predisposes the offspring to NAHR, favoring the generation of this 
microdeletion [9]. This mechanism is similar to that described for predisposing inversion 
polymorphisms in other microdeletion syndromes, such as Williams-Beuren syndrome 
(WBS), Angelman syndrome, Sotos syndrome [10], and 15q13.3 microdeletion syndrome 
[11]. For several chromosomal loci subject to NAHR, reciprocal deletion and duplication 
syndromes have been identified, including WBS and 7q11.23 duplication [12], Smith-
Magenis syndrome and Potocki-Lupski syndrome [13], Prader-Willi syndrome/Angelman 
syndrome and 15q11q13 duplication [14], Velocardiofacial syndrome and 22q11.2 
duplication [15]. However, deletions are generated at a higher rate than their reciprocal 
duplications [16]. The first case of duplication of the 17q21.31 region was not described until 
2007 [17], in a patient with severe psychomotor developmental delay, facial dysmorphism, 
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macrocephaly, abnormally broad fingers and toes and hirsutism. Four other patients with 
17q21.31 microduplication and behavior problems and poor social interaction have also 
recently been reported [18]. 
 
With the use of higher resolution arrays, taking frequent copy number variations in normal 
controls into account, the minimal critical region involved in this 17q21.31 microdeletion 
syndrome was recently refined to a 424 kb region encompassing at least six genes: C17orf69, 
the corticotropin-releasing hormone receptor 1 gene (CRHR1) (MIM #122561), the 
intramembrane protease 5 gene (IMP5) (MIM #608284), the microtubule-associated protein 
tau gene (MAPT) (MIM #157140), the saitohin gene (STH) (MIM #607067), and KIAA1267 
[19]. MAPT seems to be the most interesting of these genes for further study, because it is 
strongly expressed in the brain and has been implicated in several neurodegenerative diseases 
[20]. 
 
The largest series of patients with 17q21.31 microdeletion syndromes reported to date was 
studied by Koolen et al. [19], who identified a clinically recognizable phenotype, including 
developmental delay, childhood hypotonia and facial dysmorphism. This phenotype was 
recently expanded to include aortic root dilatation, recurrent joint dislocation, conductive 
hearing loss, dental abnormalities, the persistence of fetal fingertip pads [21], iris-choroid 
coloboma and partial situs inversus [22]. 
 
We present here a new series of 14 patients with the 17q21.31 microdeletion syndrome 
ascertained through the network of French array CGH platforms (http://www.renapa.univ-
montp1.fr/) and the BACH database (https://www.genopole-lille.fr/bach/menu.php), 
confirming the described phenotype, refining the minimal critical region and providing further 
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support for the role of MAPT in this syndrome. We also discuss the results of H1/H2 
genotyping and parent-of-origin analysis, comparing our results with published findings. 
 
Materials and methods 
Patients 
A collaborative study involving the French array CGH platforms analyzing patients with 
mental retardation (MR), dysmorphic features and multiple congenital abnormalities (MCA) 
was set up for the molecular and clinical characterization of all unpublished French patients 
carrying the 17q21.31 microdeletion. Molecular cytogenetics analyses of 2672 MR/MCA 
patients showed that 14 of these patients had a 17q21.31 microdeletion. Informed consent for 
genetic testing was obtained from all tested patients and their relatives. 
 
Molecular cytogenetics 
Two platforms were used for genomic copy number analyses, which were carried out 
according to the manufacturer's protocol (Agilent Technologies, Santa Clara, CA, USA): the 
Human Genome CGH Microarray 44K (for all patients except patient 7) and 244K (patient 7). 
Data were processed with Feature Extraction (v. 9.1) software and results were interpreted 
with CGH analysis (v. 4.0) software (Agilent
®
). When a 17q21.31 deletion was identified by 
array CGH, the microrearrangement was confirmed either by FISH with various probes 
(RP11-597L17 or RP11-656O14 targeting CRHR1, RP11-413P22, RP11-669E4 or RP11-
769P22 targeting MAPT) or by multiplex ligation-dependent probe amplification (MLPA) 
with the SALSA kit P245 from MRC-Holland (Amsterdam, the Netherlands) 
(www.mlpa.com). 
 
Genotyping for H1 and H2, and parent-of-origin analysis 
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When material from the parents was available, a family study was performed (12 patients). 
H1/H2 genotyping was carried out for individuals with the 17q21.31 deletion and their 
parents, by PCR amplification of a region encompassing a potential 238 bp deletion in the 
intron 9 of the MAPT gene associated with the H2 background [9,19]. 
 
The parental origin of the chromosome with the deletion was determined with the DG17S142 
dinucleotide marker and three to five additional variable number tandem repeats within the 
deleted region, together with two flanking short tandem repeats, D17S810 and D17S920 [19]. 
Marker analyses were carried out according to standard procedures and data were interpreted 
with GeneMapper (v. 4.0) software (Applied Biosystems, Foster City, CA, USA). 
 
Results 
Array CGH results 
All the patients studied had an overlapping heterozygous deletion of the 17q21.31 interval 
(Fig. 1). Oligonucleotide array CGH data identified a 493 kb region (chr17:41,073,486-
41,566,599) (hg18-build36) as deleted in 11 affected individuals. In one patient (patient 7), 
the deletion was larger, being somewhere between 675 kb and 810 kb in size and extending to 
the distal part of the chromosome. However, the distal breakpoint region was a site of 
frequent copy number variation (CNV) in normal controls. The proximal breakpoint was also 
found to be located in a variable region. This may account for the subtle shifts in the 
breakpoints observed, as in patient 10 (chr17:41,212,860-41,566,599) (hg18-build36). By 
contrast, patient 3 had a significantly smaller deletion, of only 205 kb (chr17:41,310,123-
41,515,622) (hg18-build36). 
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FISH studies confirmed the 17q21.31 deletion in patients 1, 2 and 4 to 13, with  RP11-
597L17 and/or RP11-656O14, RP11-413P22, RP11-669E4 or RP11-769P22 found to be 
deleted. The deletion identified in patient 3 was validated by MLPA, which confirmed the 
presence of a heterozygous deletion for the two probes targeting MAPT exons 8 and 11, 
whereas the signal obtained for the CRHR1 probe (exon 8) showed that this gene was not 
deleted (data not shown).  
 
Clinical description (Table 1) 
The most typical clinical features of 17q21.31 syndrome include hypotonia, developmental 
delay, overly friendly/amiable behavior and facial dysmorphism with a long face, a tubular or 
pear-shaped nose and a bulbous nasal tip (Fig. 2). The principal clinical characteristics of 
patients 1 to 14 are described in Table 1. Additional features are described below. 
 
Patient 1 is the first and only child of unrelated parents. The pregnancy was 
complicated by intrauterine growth retardation (IUGR), which was interpreted as originating 
from a vascular cause. This child, a boy, was born at 39 weeks by cesarean section. Early 
problems included an inability to suck effectively and feeding problems, with enterocolitis 
causing ulcer and necrosis. Molecular analysis of the GJB2 and GJB6 genes were performed 
because of deafness, but no alteration was detected. 
Patient 2 is the second child of Moroccan and Breton parents. Prenatal imaging 
showed right hydronephrosis. A ventricular septal defect (VSD) observed at birth regressed 
spontaneously. This patient presented bronchiolitis and pyelonephritis at the age of six 
months, feeding problems, fainting due to hypotonia at the age of nine months, and epileptic 
seizures at the age of three years. He has a short stature and low weight (-2SD) and is prone to 
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frequent falls. He has discrete aortic dilatation, with measurements at the upper limit of the 
normal range (27.3 mm aortic sinus at 15 ½ years of age, 28.5 mm at 17 years). 
Patient 3 is the first child of healthy unrelated parents. The pregnancy was 
characterized by a hygroma colli during the first trimester and multicystic right renal 
dysplasia. An ischemic infarction of the superficial middle cerebral artery territory, on the  
right side, was diagnosed in the neonatal period and probably occurred before birth. It resulted 
in fronto-parietal ischemic sequelae, initially in the form of symptomatic ipsilateral temporo-
occipital hemorrhage, subsequently progressing to cortico-subcortical atrophy. Explorations 
carried out during and after the early postnatal period demonstrated significant asymmetry in 
the development of the two hemispheres of the brain. At the age of 16 months, this patient 
still presents axial hypotonia, with an unstable sitting posture and retropulsion episodes. 
Patient 4 is a quiet child. Skin lesions were reported for this patient, with numerous 
nevi, including a hairy nevus on the face, a depigmented patch of the base of the neck and a 
pigmented spot on the left nipple. 
Patient 5 was born after a pregnancy complicated by IUGR. This patient, born to 
patients from a gypsy background, had a number of skin lesions, including generalized 
hyperpigmentation, a pigmented spot on the left side of the front of the neck, a depigmented 
patch above the left nipple and numerous nevi, including one on the right sole and another on 
the left hand.  
Patient 6 presented initial hypotonia, followed by seizures at the age of 14 months. 
His testes were located in the inguinal canal.  
Patient 7 was delivered at 31 weeks of gestation, by cesarean section due to acute 
fetal distress. Scaphocephaly was recorded, leading to the detection of metopic craniostenosis 
at the age of two years.  
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Patient 8 presented feeding difficulties in the neonatal period. Severe speech 
dyspraxia became apparent in infancy.  
Patient 9 is the second child of non consanguineous parents. She was hypotonic as a 
baby, with tongue protrusion. She also presented feeding difficulties and constipation. 
Patient 10 is the third child of unrelated parents. The pregnancy was uncomplicated. 
A bilateral cleft lip was discovered at birth, with no damage to the alveolar ridge or palate. 
This patient is very sociable and cheerful. Her skin is very dry. 
Patient 11 presented delayed development of axial tonus at four months. Seizures first 
appeared at the age of eight months, with temporo-occipital foci.  
Patient 12 presented hypotonia and feeding difficulties during the neonatal period. He 
also displayed cryptorchidism requiring surgical treatment. 
Patient 13 presented developmental delay, more serious for psychomotor 
development than for language.  
For patient 14, the neonatal period was marked by feeding difficulties and hypotonia.  
 
Genotyping 
The genotyping of 24 parents (in 12 families) showed that the deletion was inherited from the 
mother in seven families and from the father in four families. In the remaining family, the 
panel of repeat markers across the deleted region could not distinguish between the parental 
chromosomes (Table 2). 
 
Fifteen of the 24 parents tested were heterozygous for the H2 inversion, whereas four were 
homozygous for this inversion. The parent from which the inversion originated carried the H2 
inversion polymorphism in at least a heterozygous state. 
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Discussion 
 
All the patients with 17q21.31 microdeletion syndrome reported here were identified by array 
CGH screening, by the network of French array CGH platforms, of large heterogeneous 
cohorts of patients with mental retardation. The calculated prevalence of 17q21.31 syndrome 
in our French cohort was 0.52% (14 of the 2672 patients tested), which is of the same order of 
magnitude as previous estimates (0.64% for Koolen et al.
 
[19], 0.5% for Sharkey et al. [22]).  
 
Given the copy number polymorphisms located at either end of the deleted region, we 
investigated the size of the deletion in 11 of our patients conforming to the DECIPHER 
description of 17q21.31 syndrome as a standard deletion extending from 40.99 to 41.57 Mb. 
However, the critical region of 17q21.31 was recently refined and narrowed to a 424 kb 
genomic interval (chr17:41,046,729-41,470,954, hg18) by analyses based on SNP arrays and 
ultra-high density custom oligonucleotide arrays targeting the 17q21.31 region and excluding 
frequent copy number variations in normal controls [19]. In our patient 3 with classical 
clinical characteristics, including facial features (Fig. 2), a smaller, partially overlapping 
deletion was observed (chr17:41,310,123-41,515,622, hg18-build36). This deletion 
encompasses only MAPT, STH and KIAA1267, leaving the patient with two copies of the 
CRHR1 gene, but the phenotype of this patient was no milder than that of the other patients. 
Comparison of this 205 kb deletion with the 424 kb critical region described by Koolen et al. 
[19] defined a new minimal critical region of 160.8 kb (chr17:41,310,123-41,470,954, hg18), 
providing strong evidence for the involvement of of the MAPT (microtubule-associated 
protein Tau) gene (MIM #157140) in this syndrome. Gain-of-function mutations in MAPT 
have been identified in neurodegenerative diseases, such as autosomal dominant frontal-
temporal dementia with parkinsonism [23,24], supranuclear bulbar palsy and corticobasal 
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degeneration [25], or Alzheimer’s disease [26], in which abnormal deposition of insoluble tau 
protein is observed, with a decrease in the concentration of the normal soluble tau molecule in 
patients’ brains, affecting the assembly, dynamic behavior and spatial organization of 
microtubules in neurons and glial cells [27]. The microdeletion event observed in 17q21.31 
syndrome results in MAPT haploinsufficiency. In mice, Mapt haploinsufficiency in tau -/- 
animals affects microtubule density and stability in small-caliber axons [28], resulting in a 
murine phenotype including muscle weakness in a wire-hanging test, hyperactivity in a novel 
environment and impairment in contextual fear conditioning [29]. However, screening for 
mutations in MAPT in 122 individuals with a phenotype suggestive of 17q21.31 syndrome 
identified no disease-associated variants [19]. 
 
The facial features described by other groups [19,21] was found in our patients, but become 
increasingly obvious with age. Consistent with one patient described by Tan et al. [21], two of 
our patients presented scaphocephaly revealing metopic craniostenosis. All our patients were 
hypotonic, with global developmental delay predominant over language problems. Other 
defects (ophthalmologic, cardiac, urologic, central nervous system, joint hypermobility, hip 
dysplasia) were commonly noted. Prenatal ischemic infarction was diagnosed in patient 3, as 
also reported for one of the patients described by Koolen et al. [19]. Tan et al. [21] reported 
hearing defects resulting from chronic otitis. One of our patients (patient 1) was deaf, but this 
problem was due to a neurosensorial defect rather than conductive problems, despite the 
occurrence of numerous ENT infections in early infancy.  
 
The 17q21.31 genomic region contains a 900 kb inversion polymorphism generating two 
highly divergent haplotypes, H1 and H2, that are transmitted en bloc [9]. The frequency of the 
H2 lineage has been reported to be about 20% in the European population, whereas this 
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haplotype is rare in Africans and almost never detected in East Asians. We indirectly 
identified this H2 inversion in 23 of the 48 chromosomes from parents tested and, for each 
trio, the parent from which the chromosome 17 deletion was inherited carried the H2 
inversion polymorphism in either the homozygous or heterozygous state, giving a 
significantly higher frequency. Seven of the deletions were of maternal origin and four were 
of paternal origin. Combining these data with those obtained by Koolen et al. [19], we can 
assume that there is no significant bias in the parental origin of the chromosome bearing the 
deletion. Unfortunately, we were unable to obtain DNA from the parents of patient 3. The H2 
haplotype confers a genomic architecture in which LCR subunits are directly oriented, 
mediating the NAHR event leading to deletion [30]. However, as the frequency of 17q21.31 
deletion in the offspring of H2 inversion carriers is low, the H2 allele is necessary, but not 
sufficient to generate the 17q21.31 deletion [19]. 
 
Considering our French series of 14 patients with the 17q21.31 microdeletion syndrome and 
previous reports of 22 [19] and 11 patients [21], it is clear that this microdeletion syndrome is 
clinically significant. Our study also narrowed the definition of the minimal deleted region to 
a restricted interval of 160.8 kb, strengthening the implication of the MAPT gene in this 
syndrome. 
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Electronic databases 
 
Network of the French array CGH platforms: Réseau AChro-Puce (Réseau d’Analyse 
Chromosomique sur Puces à ADN) http://www.renapa.univ-montp1.fr/ 
BACH database: https://www.genopole-lille.fr/bach/menu.php 
UCSC Genome Browser on Human March 2006 Assembly – hg18: 
http://genome.ucsc.edu/cgi-bin/hgGateway?org=human. 
Database for Genomic Variants: http://projects.tcag.ca/variation 
DECIPHER Consortium: https://decipher.sanger.ac.uk/ 
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Figure legends 
Figure 1. Schematic diagram of 17q21.31 rearrangements, indicating relative sizes and 
positions, as currently defined within the DECIPHER Consortium, described by Koolen et al. 
2008 and observed in 14 patients on the basis of array CGH data. Beneath the 17q21.31 
chromosome map, the two right-angled double-headed arrows indicate sites of frequent copy 
number variation (CNV) in normal controls, often overlapping the proximal and distal ends of 
classical deletions. Below the various patients with deletions, the double-headed arrow shows 
the new minimal critical region of 160.8 kb, providing further evidence for the involvement of 
MAPT in 17q21.31 microdeletion syndrome. 
Figure 2. Facial photographs of ten patients with 17q21.31 deletions: from left to right, 
patients 1, 2, 3, 4 in the upper panel; patients 5, 6 , 7, 8 in the middle panel; patients 9 and 11 
in the lower panel.  
Table I. Clinical characteristics of patients with 17q21.31 deletions 
Table II. Genotyping for H1/H2 and parent-of-origin results 
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  Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 
Age at time of report 7 years 18 years 1 year > 18 years 14 years 5 years 5 years 
Sex M M F M M M M 
Perinatal 
Birth weight 
 
Birth length 
 
Birth HC 
 
 
2710 g at 39 WG 
(3
rd
-10
th
 percentile) 
47 cm 
(10
th
 percentile) 
34 cm 
(50
th
 percentile) 
 
2990 g at 40 WG 
(10
th
 percentile) 
45,5 cm 
(<3
rd
 percentile) 
35 cm 
(50
th
 percentile) 
 
2360 g at 40WG  
(< 3
rd 
percentile) 
46 cm 
(< 3
rd
 percentile)  
34 cm 
(25
th
-50
th
 percentile) 
 
3400 g at 42 WG 
(25
th
 percentile) 
50 cm 
(25
th
 percentile) 
36 cm 
(50
th
-75
th
 percentile) 
 
2270 g at 38 WG 
(3
rd
 percentile) 
47 cm 
(10
th
-25
th
 percentile) 
34 cm 
(25
th
-50
th
 percentile) 
 
2300 g at 37 WG 
(3
rd
 percentile) 
47 cm 
(10
th
-25
th
 percentile) 
32.5 cm 
(25
th
 percentile) 
 
1260 g at 31 WG 
(10
th
-25
th
 percentile) 
38 cm 
(10
th
-25
th
 percentile) 
28 cm 
(10
th
-25
th
 percentile) 
Hypotonia + + +   + + 
Developmental delay + + 
Walked at 21 
months 
+ + +  + 
Language delay + + +    + 
Overly friendly 
disposition 
+ 
 
 
Behavioral 
problems 
+    + 
ADHD 
Facial features 
 
Large and broad 
nasal tip, full 
philtral pillars, 
large and low-set 
ears, often open 
mouth, thin upper 
lip, 
hypermetropia, 
astigmatism 
High and broad 
forehead, large 
and protruding 
ears, gingival 
pads, mild myopia 
Bilateral 
epicanthus, 
hypertelorism, 
abnormal ears, 
tongue protrusion 
Synophrys, 
prognathism, 
absence of upper 
incisors, thick lips, 
large ears, eye 
nystagmiform 
movements and 
lens puncture 
Cleft lip and 
palate, 
hypertelorism, 
bilateral 
epicanthus, broad 
nasal root 
Hypertelorism, 
epicanthus, 
forehead 
protrusion, 
strabism, everted 
lip, hypoplastic 
columella 
Bulbous nasal tip, 
low-set ears, short 
philtrum, 
upslanting 
palpebral fissures, 
astigmatism 
Skin, nails, hair Silky skin Elastic skin  Numerous nevi, 
abnormal 
pigmentation 
Numerous nevi, 
abnormal 
pigmentation 
 Silky skin 
Feeding problems + + + -    
CNS defects  Recurrent seizures 
between 3 and 5 
years of age 
- MRI: broad lateral 
ventricles  
MRI: thinning of 
the posterial third 
of the corpus 
Seizures at 14 
months. 
MRI: thin corpus 
MRI: partial 
agenesis of the 
corpus callosum, 
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MRI: dysgenesis 
of corpus 
callosum 
callosum, 
abnormally shaped 
hippocampus 
callosum, bilateral 
subependymal 
heterotopia 
mild ventricle 
broadening 
Cranial abnormalities Microcephaly  
(- 3 SD) 
 Scaphocephaly -  - Scaphocephaly 
Metopic 
craniostenosis 
Heart defects ASD, VSD VSD, aortic 
dilatation 
ASD, VSD -  - - 
Kidney and urologic 
defects 
Shawl scrotum Right 
hydronephrosis, 
bilateral 
cryptorchidism, 
phimosis 
Right multicystic 
renal dysplasia  
 Bilateral 
cryptorchidism 
Bilateral 
cryptorchidism 
Hypospadias 
Spine abnormalities  -  Scoliosis   - 
Musculoskeletal 
problems 
Joint hyperlaxity, 
hip dysplasia, 
digital pads, toe 
deviation 
Hyperlaxity, 
numerous 
fractures and 
sprains 
 -   Mild finger and 
wrist laxity 
Deafness Bilateral 
perception 
deafness 
- - - - - - 
Other Chronic 
constipation, 
bilateral inguinal 
hernia, 
chronic ENT 
infections 
Anus fistula 
Chronic ENT 
infections 
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 Patient 8 Patient 9 Patient 10 Patient 11 Patient 12 Patient 13 Patient 14 
Age at time of 
report 
1 year  14 years 7 years 13 years 17 years 8 years 
Sex F F F M M M F 
Perinatal 
Birth weight 
 
Birth length 
 
Birth HC 
 
 
2600 g et 39 WG 
(3
rd
-10
th
 percentile) 
 
3170 g at 39 WG 
(25
th
-50
th
 percentile) 
49 cm 
(50
th
 percentile) 
33 cm 
(10
th
-25
th
 percentile) 
 
3300 g at 39 WG 
(50
th
-75
th
 percentile) 
51 cm 
(75
th
-90
th
 percentile) 
36 cm 
(90
th
 percentile) 
 
3300g at 40 WG 
(25
th
-50
th
 percentile) 
50 cm 
(25
th
-50
th
 percentile) 
35 cm 
(50
th
 percentile) 
 
2360g at 39.5 WG 
(<3
rd
 percentile) 
 
2700 g at 38 WG 
(10
th
-25
th
 percentile) 
48 cm 
(25
th
 percentile) 
34 cm 
(25
th
-50
th
 percentile) 
 
2450 g at 38 WG 
(10
th
-25
th
 percentile) 
48 cm 
(50
th
-75
th
 percentile) 
33 cm 
(25
th
-50
th
 percentile) 
Hypotonia + + + + + - + 
Developmental 
delay 
+ + 
Walked at 24 
months 
+ 
Walked at 18 
months 
+ 
Walked at 24 
months 
+ 
Walked at 24 
months 
+ + 
Language delay + + + + + + + 
Overly friendly 
disposition 
+ + + + 
ADHD 
+ + + 
Facial features 
 
Low everted lip, 
bulbous nasal tip, 
low-set ears 
Flattened nose, 
everted lower lip, 
tongue protrusion, 
abnormal ears 
Long face, shaggy 
eyebrows, 
downslanting 
palpebral fissures, 
bulbous nasal tip, 
bilateral cleft lip, 
long and fleshy ear 
lobes 
“Pear-shaped” 
nose, long face, 
low-set and large 
ears, strabism 
Tubular “pear-
shaped” nose, long 
face, low-set ears, 
strabism, 
hypermetropia 
Tubular “pear-
shaped” nose, long 
face, 
hypermetropia, 
astigmatism, small 
palpebral fissures 
Tubular “pear-
shaped” nose, long 
face 
Skin, nails, hair Hypopigmentation  Dry with keratosis     
Feeding problems + + - - + - + 
CNS defects - - - + 
First seizures at 8 
months 
- Epilepsy Seizures at 7 years 
but normal EEG 
result 
Cranial 
abnormalities 
- Microcephaly - HC at +1.66SD at 
8 years 
- Macrocrania  
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Heart defects ASD - - - - - ASD 
Kidney and 
urologic 
malformations 
Vesico-ureteric 
reflux 
- - - Cryptorchidism Unilateral 
cryptorchidism 
- 
Spine abnormalities - - - - - - - 
Musculoskeletal 
problems  
Congenital hip 
dysplasia 
 Bilateral hip 
dysplasia, 
kneecap 
dislocation, 
misimplanted and 
long toes 
Joint laxity Pectus excavatum  Hyperlaxity, long 
and slender fingers 
Deafness - - - - - - - 
Other  Chronic 
constipation 
     
 
ADHD, attention deficit hyperactivity disorder; ASD, atrial septal defect; CNS, central nervous system; ENT, ear, nose and throat; F, female; M, male; HC, Head 
circumference; SD, standard deviation; VSD, ventricular septal defect; WG, weeks of gestation 
A blank square means that the characteristic was not assessed, a “minus” signs (-) indicates that it was absent. 
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Patient Father Mother Parent-of-origin 
1 H1/H2 H1/H2 Maternal 
2 H1/H2 H1/H2 Maternal 
4 H2/H2 H1/H2 Maternal 
5 H2/H2 H1/H1 Paternal 
6 H1/H1 H1/H2 Maternal 
7 H1/H1 H1/H2 Maternal 
8 H2/H2 H1/H2 Paternal 
9 H1/H2 H2/H2 Non informative 
10 H1/H2 H1/H2 Maternal 
12 H1/H1 H1/H2 Maternal 
13 H1/H2 H1/H1 Paternal 
14 H1/H2 H1/H2 Paternal 
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